Discontinuation report LYNPARZA
Report ID | 134652 |
Drug Identification Number | 02454408 |
Brand name | LYNPARZA |
Common or Proper name | olaparib |
Company Name | ASTRAZENECA CANADA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | OLAPARIB |
Strength(s) | 50MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL ORAL |
Packaging size | Bottle of 112 capsules |
ATC code | L01XX |
ATC description | OTHER ANTINEOPLASTIC AGENTS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2021-12-01 |
Actual discontinuation date | 2021-01-11 |
Remaining supply date | 2021-01-11 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | There are no known supply of this drug available for sale on the market |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: medinfo.canada@astrazeneca.com. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2021-02-25 | French | Compare |
v2 | 2021-02-25 | French | Compare |
v1 | 2021-02-25 | English | Compare |
Showing 1 to 3 of 3